Top Markets
#1 Siren Siren +118.41%
#2 Block Street Block Street +102.26%
#3 DAO Maker DAO Maker +51.38%
#4 FARCANA FARCANA +45.98%
#5 MemeCore MemeCore +44.44%
#6 Win Win +37.10%
#7 Amiko Amiko +34.17%
#8 Succinct Succinct +30.04%
#9 Layer3 Layer3 +23.83%
#10 Green Green +22.13%
Coin of the day
Siren Siren
Settings
Language
ENGLISH
Currency
USD
Theme
Novartis AG Novartis AG

Novartis AG

NVS
Rank in Stocks #47
Novartis AG researches, develops, manufactures, and markets healthcare products... Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Share Price
$150.75
Market Cap
$291.41B
Change (1 day)
1.44%
Change (1 year)
29.29%
Country
CH
Trade Novartis AG (NVS)

Category

Healthcare
P/E ratio for Novartis AG (NVS)
P/E ratio as of 2026 TTM: 0
According to Novartis AG latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Novartis AG from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Eli Lilly Eli Lilly
Eli Lilly
LLY.US
 42.86 -
US
AstraZeneca PLC AstraZeneca PLC
AstraZeneca PLC
AZN.US
 28.47 -
GB
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 21.88 -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 92.55 -
US
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 15.77 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.